Immunic (IMUX) Other financing activities (2013 - 2026)

Immunic (IMUX) has 13 years of Other financing activities data on file, last reported at $187.3 million in Q1 2026.

• For the quarter ending Q1 2026, Other financing activities changed N/A year-over-year to $187.3 million; the trailing twelve-month figure through Mar 2026 stood at $187.4 million (up 243335.06% YoY), and the FY2025 full-year result was $182000.0, up 136.36% from the prior year.
• Other financing activities grew to $187.3 million in Q1 2026, from $59000.0 in the prior quarter.
• In the past five years, Other financing activities ranged from a high of $187.3 million in Q1 2026 to a low of -$125000.0 in Q4 2022.
• A 5-year average of $18.8 million and a median of $55000.0 in 2023 frame the typical range for Other financing activities.
• Peak annual rise in Other financing activities reached 920.0% in 2023, while the deepest fall reached 64.0% in 2023.
• Tracing IMUX's Other financing activities over 5 years: stood at -$125000.0 in 2022, then jumped by 64.0% to -$45000.0 in 2023, then jumped by 271.11% to $77000.0 in 2024, then dropped by 23.38% to $59000.0 in 2025, then jumped by 317294.92% to $187.3 million in 2026.
• Business Quant data shows IMUX's Other financing activities at $187.3 million in Q1 2026, $59000.0 in Q4 2025, and $123000.0 in Q2 2025.